

**Presentation Type:**

Poster Presentation

**Subject Category:** Long-Term Care

**Racial Differences in Infection Management and Palliative Care at End-of-Life in Nursing Homes Nationwide**

Leah Estrada; Andrew Dick; Patricia Stone and Jordan Harrison

**Background:** Infections are common at end-of-life in older nursing-home residents. This often leads to the overuse of antibiotics and burdensome treatments. Improving infection management through palliative care at the end of life has been proposed as a key strategy to reducing inappropriate antibiotic use. Black nursing-home residents tend to reside in poorly performing nursing homes. We examined palliative care services in nursing homes with varying proportions of black residents. **Methods:** Cross-sectional, nationally representative nursing-home survey data (2017–2018) was combined with the Minimum Data Set 3.0 (nursing-home resident characteristics), the Certification and Survey Provider Enhanced Reporting data (nursing-home facility characteristics), and the Multidimensional Deprivation Index (county-level poverty estimates). The survey included 24 validated items on nursing-home palliative care services, as well as the nursing home’s infection control program and integration of infection management and palliative care (summative score, 0–100). We used nursing-home facility-level multivariate regression to estimate the relationship between proportion of black residents and palliative care scores, before and after controlling for county-level poverty estimates, facility characteristics, and resident characteristics. We categorized proportion of black residents using methods reported in the literature (25%). **Results:** The mean weighted palliative-care score in our sample of 869 nursing homes (weighted n = 15,020) was 47.7 (SE, 0.70). In unadjusted analyses, nursing homes with higher proportions of black residents provided significantly fewer palliative care services than nursing homes with no black residents, with the greatest differences ( $P = .027$ ) observed between nursing homes with >25% black residents (mean palliative care score, 43.82; SE, 2.31) versus nursing homes with no black residents (mean palliative care score, 49.47; SE, 1.08). These disparities persisted after adjustment for urbanicity and county-level poverty rates ( $p < 0.01$ ) but were attenuated after further adjustment for resident and facility level characteristics ( $p = 0.138$ ). **Conclusions:** Our findings demonstrate that wide variations in nursing-home palliative-care services exist with increased proportions of black residents, even after accounting for community characteristics. Further research is needed to identify and understand the specific community characteristics that play a role in the provision of palliative care services. Palliative care is a method to reduce inappropriate antimicrobial use at the end of life and should be expanded with a focus on nursing homes with higher proportions of black residents.

**Table 1.** Mean palliative care scores by nursing home

	n	%	PC Services Score Mean (SE)	p-value
<b>All Nursing Homes</b>	15,020	100		
<b>Proportion of Black Residents</b>				
0	5,794	38.58%	49.487 (1.08)	0.077
< 3%	1,853	12.33%	49.807 (1.97)	
3–10%	3,439	22.89%	46.749 (1.43)	
>10–25%	2,101	13.99%	45.510 (1.89)	
>25%	1,834	12.21%	43.815 (2.31)	

**Funding:** No

**Disclosures:** None

*Antimicrobial Stewardship & Healthcare Epidemiology* 2021;1(Suppl. S1):s69

doi:10.1017/ash.2021.133

**Presentation Type:**

Poster Presentation

**Subject Category:** MDR GNR

**Evaluation of Ceftolozane/Tazobactam, Ceftazidime/Avibactam and Meropenem/Vaborbactam Against Multidrug-Resistant (MDR) *Pseudomonas***  
Haider Shamsulddin; Jeffrey Lin; Julie Ribes and Thein Myint

**Background:** Data on the patient outcomes for newer  $\beta$ -lactam- $\beta$ -lactamase inhibitor (BLBI) drugs compared to carbapenem-containing

**Table 1: Baseline characteristics and patient outcomes**

	New Beta Lactam - beta lactamase inhibitor combination *** (N=51)		Carbapenems and Other Antibiotics **** (N=92)		P-value
	Number	Percentage	Number	Percentage	
Mean Age	49		54		*0.06
<b>Patient Characteristics</b>					
Male	32	62.75%	61	66.30%	0.67
Blood Culture	31	60.78%	36	39.13%	<b>0.01</b>
Respiratory Culture	11	21.57%	63	68.48%	<b>&lt;0.001</b>
Diabetes Mellitus	11	21.57%	25	27.17%	0.45
Immunosuppressed	21	41.18%	41	44.57%	0.69
Malignancy	13	25.49%	19	20.65%	0.51
Transplant	8	15.69%	26	28.26%	0.09
<b>Outcomes</b>					
AKI	16	32.00%	56	60.87%	<b>&lt;0.001</b>
Readmission	6	11.76%	16	17.39%	0.37
Mean Length of Stay (LOS) days	22.6		37.8		<b>*0.01</b>
**Duration of Bacteremia (IQR) days	2		3		*0.34
90-Day Mortality	10	19.61%	46	50.00%	<b>&lt;0.001</b>
<b>Initial source of infection</b>					
UTI	13	25.49%	8	8.70%	<b>0.007</b>
Pneumonia	27	52.94%	62	67.39%	0.09
Line related	1	1.96%	4	4.35%	<b>**0.4</b>
Abdomen	5	9.80%	18	19.57%	0.13

\*T test unequal sample variances (one tailed)

\*\* Fisher exact test

\*\*\* Newer beta lactams include ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam

\*\*\*\* Other antibiotics include one or more of the following: cefepime, piperacillin/tazobactam, gentamicin, tobramycin, or amikacin.

**Table 1: Baseline characteristics and patient outcomes**

	New Beta Lactam - beta lactamase inhibitor combination *** (N=51)		Carbapenems and Other Antibiotics **** (N=92)		P-value
	Number	Percentage	Number	Percentage	
Mean Age	49		54		*0.06
<b>Patient Characteristics</b>					
Male	32	62.75%	61	66.30%	0.67
Blood Culture	31	60.78%	36	39.13%	<b>0.01</b>
Respiratory Culture	11	21.57%	63	68.48%	<b>&lt;0.001</b>
Diabetes Mellitus	11	21.57%	25	27.17%	0.45
Immunosuppressed	21	41.18%	41	44.57%	0.69
Malignancy	13	25.49%	19	20.65%	0.51
Transplant	8	15.69%	26	28.26%	0.09
<b>Outcomes</b>					
AKI	16	32.00%	56	60.87%	<b>&lt;0.001</b>
Readmission	6	11.76%	16	17.39%	0.37
Mean Length of Stay (LOS) days	22.6		37.8		<b>*0.01</b>
**Duration of Bacteremia (IQR) days	2		3		*0.34
90-Day Mortality	10	19.61%	46	50.00%	<b>&lt;0.001</b>
<b>Initial source of infection</b>					
UTI	13	25.49%	8	8.70%	<b>0.007</b>
Pneumonia	27	52.94%	62	67.39%	0.09
Line related	1	1.96%	4	4.35%	<b>**0.4</b>
Abdomen	5	9.80%	18	19.57%	0.13

\*T test unequal sample variances (one tailed)

\*\* Fisher exact test

\*\*\* Newer beta lactams include ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam

\*\*\*\* Other antibiotics include one or more of the following: cefepime, piperacillin/tazobactam, gentamicin, tobramycin, or amikacin.

combination antibiotics for multidrug-resistant (MDR)–*Pseudomonas aeruginosa* infections are limited. **Methods:** This retrospective, case–control observational study was based on chart review of the patients managed at the University of Kentucky. **Results:** In total, 143 patients with MDRO *Pseudomonas aeruginosa* infections were identified and divided into 2 groups: 1 group received newer BLBI combinations with or without aminoglycosides or polymyxins, for at least 72 hours, and the control group received carbapenem containing combination antibiotics or other antibiotics. Baseline characteristics and patient outcomes are shown in Table 1. **Discussion:** The newer BLBI combinations group consisted of 60.8% MDR *Pseudomonas* bacteremia, whereas the control group had 68.4% of MDR *Pseudomonas* respiratory cultures. Overall, the use of newer BLBI combinations such as ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam was associated with lower rates of acute kidney injury (AKI), shorter LOS, and lower mortality rates compared to the control group, and these differences were statistically significant. Because the 2 populations of patient differed significantly based on the site of infection (sepsis vs pneumonia), the data were reanalyzed to evaluate the impact of therapy on the occurrence of AKI, LOS, and mortality based on the site of infection. Only those patients with sepsis who received the newer combination drugs had significantly better rates of AKI, lower LOS, and had lower rates of mortality. The 2 treatment arms were not statistically different when comparing patients with pneumonia. Additionally, the use of these new combination therapies did not make a difference regarding readmission rates or duration of bacteremia for the patients included in the study.

**Funding:** No

**Disclosures:** None

*Antimicrobial Stewardship & Healthcare Epidemiology* 2021;1(Suppl. S1):s69–s70

doi:10.1017/ash.2021.134

#### **Presentation Type:**

Poster Presentation

**Subject Category:** MDR GNR

**Time Above All Else: Pharmacodynamic Analysis of B-Lactams in Critically Ill Patients**

Katherine Landmesser; David Burgess and Justin Clark

**Background:** Despite the development of new  $\beta$ -lactam agents, gram-negative resistance continues to be an increasing concern in the healthcare setting. The understanding and optimizing antimicrobial pharmacokinetics and pharmacodynamics are essential to enhance activity of appropriate therapy, improve clinical outcomes, and reduce the development of resistance. **Methods:** A pharmacodynamic analysis was performed for 4  $\beta$ -lactams (aztreonam, cefepime, piperacillin/tazobactam, and meropenem) and 14 dosage regimens as either intermittent bolus (IB) or prolonged infusion (PI) against 7 gram-negative pathogens: *Klebsiella pneumoniae*, *K. oxytoca*, *Escherichia coli*, *Enterobacter cloacae*, *E. aerogenes*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*. Unit-specific minimum inhibitory concentration (MIC) distribution data were generated using antibiogram data over a decade for 4 intensive care units within our institution: medical ICU, cardiovascular ICU, surgical ICU, and neurosurgical ICU. Published pharmacokinetic parameter estimates in critically ill patients, combined with this MIC distribution data, were utilized to perform Monte Carlo simulations for each antimicrobial regimen. The percentage of time for which the unbound concentration of antibiotic remained above the MIC ( $fT > MIC$ ) was utilized as the pharmacodynamic target for each agent: 40%  $fT > MIC$  for meropenem, 50%  $fT > MIC$  for piperacillin/tazobactam, 60%  $fT > MIC$  for aztreonam, and 70%  $fT > MIC$  for cefepime. Regimens were modeled using Oracle Crystal Ball software to determine the likelihood of achieving  $>90\%$  probability of target attainment (PTA). Because resistance rates were significantly higher for *P. aeruginosa* and *A. baumannii*, cumulative PTAs for *K. pneumoniae*, *K. oxytoca*, *E. coli*, *E. cloacae*, and *E. aerogenes* were analyzed separately to determine the relative PTA for Enterobacterales in each ICU. **Results:** No intermittent infusion regimens of piperacillin/tazobactam, aztreonam, or cefepime achieved  $>90\%$  PTA for any organism. Piperacillin/tazobactam 4.5 g infused over 4 hours (PI q6h) and aztreonam 2 g PI q6h failed to achieve adequate PTA for Enterobacterales with only 84% and 85% PTA, respectively. For Enterobacterales, the only regimens to achieve  $>90\%$  PTA

included cefepime 2 g infused over 3 hours (PI q8h) and meropenem 1g IB q8h with 95% and 99% PTA, respectively. Meropenem 2 g PI q8h was the only regimen capable of achieving  $>90\%$  PTA for both *A. baumannii* and *P. aeruginosa* with 97% and 92% PTA, respectively. **Conclusions:** Although utilization of high doses and prolonged infusions dramatically improve the pharmacodynamics of  $\beta$ -lactam therapy, the only regimen capable of achieving adequate PTA for all organisms analyzed was meropenem 2g PI q8h. To reduce carbapenem use, combination therapy may be considered for critically ill patients receiving aztreonam, cefepime, or piperacillin/tazobactam for empiric treatment of gram-negative infections.

**Funding:** No

**Disclosures:** None

*Antimicrobial Stewardship & Healthcare Epidemiology* 2021;1(Suppl. S1):s70

doi:10.1017/ash.2021.135

#### **Presentation Type:**

Poster Presentation

**Subject Category:** MDR GNR

**Difference in Susceptibility Between Carbapenemase- and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae**  
Justin Clark and David Burgess

**Background:** Carbapenem-resistant Enterobacteriaceae (CRE) remain among the most urgent infectious threats according to the CDC Threats Reports. Although focus has often been placed on carbapenemase-producing phenotypes, there is increasing interest in distinguishing the optimal treatment and outcomes of carbapenemase-producing (CP) and non-carbapenemase-producing (NCP) CRE. We compare antimicrobial susceptibility patterns between CP-CRE and NCP-CRE isolated from patients at our academic medical center. **Methods:** All CRE isolates of *Enterobacter cloacae*, *Escherichia coli*, *Klebsiella aerogenes*, *K. oxytoca*, and *K. pneumoniae* in adult inpatients from 2010 to 2019 were included in this study. Susceptibility testing was performed using the BD Phoenix Automated System (BD Diagnostics, Sparks, MD). CLSI susceptibility break points were utilized in the susceptibility analyses of all antimicrobials tested. To determine carbapenemase production, isolates resistant only to ertapenem were considered NCP-CRE, and those resistant to both ertapenem and meropenem were considered CP-CRE. Statistical comparisons of susceptibility profiles were performed using either the  $\chi^2$  test or the Fisher exact test. All data preprocessing and statistical analyses were performed using Python software. **Results:** Over the decade, we identified 291 CRE isolates (216 isolates resistant only to ertapenem and 75 resistant to ertapenem and meropenem). The ertapenem-resistant-only phenotype comprises  $\sim 66\%$  of the total CRE population and is largely composed of *E. cloacae* (67%). As expected, most  $\beta$ -lactam susceptibilities were negligibly low between the 2 groups; however, other clinically relevant antimicrobials (aminoglycosides, fluoroquinolones, and sulfamethoxazole/trimethoprim) exhibited starkly different susceptibility profiles ( $P$  value **Conclusions:** These findings suggest that the most predominant CRE phenotype at our institution is not carbapenemase production. Evaluation of outcomes between CP- and NCP-CRE should be pursued further. The large differences in the MIC distributions may lead to differing outcomes for the affected patients.

**Funding:** No

**Disclosures:** None

*Antimicrobial Stewardship & Healthcare Epidemiology* 2021;1(Suppl. S1):s70

doi:10.1017/ash.2021.136

#### **Presentation Type:**

Poster Presentation

**Subject Category:** MDR GNR

**Stewardship Nightmare: Ceftolozane/Tazobactam-Resistant *Pseudomonas aeruginosa* Infections Accelerated by the COVID-19 Pandemic**

Adam Haviland; Gregory Weston; Priya Nori; Wendy Szymczak; Yi Guo and Rebecca M. Marrero Rolon

**Background:** The Centers for Disease Control and Prevention reported 32,600 cases, 2,700 deaths, and healthcare costs of 767 million dollars